Rivus Pharmaceuticals, Inc., founded in 2019, is dedicated to transforming the treatment of cardio-metabolic disease with its innovative approach. The company focuses on advancing a new class of oral, once daily, small molecule therapeutics known as Controlled Metabolic Accelerators (CMAs). These CMAs are designed to improve cellular metabolism and treat the underlying cause of prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), and cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). In their most recent funding round, Rivus Pharmaceuticals secured a noteworthy $132.00M Series B investment on 22 September 2022. The investment was backed by prominent firms such as Longitude Capital, RA Capital Management, BB Biotech Ventures, RxCapital, Medicxi, and Bain Capital Life Sciences. For more information about Rivus Pharmaceuticals, please visit their website at https://www.rivuspharma.com/. The company operates primarily in the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $132.00M | 6 |
|
22 Sep 2022 |
| Series A | $35.00M | 3 |
|
20 Jul 2021 |
No recent news or press coverage available for Rivus Pharmaceuticals .
We care about your data, and we'd love to use cookies make your experience better.
